# Ghayas C. Issa

Source: https://onco.cc/people/ghayas-issa/  
OnCo record `ghayas-issa` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.

## Summary

Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: aml; menin; targeted-therapy
- Role: Associate Professor of Leukemia, MD Anderson Cancer Center
- Specialisms: Acute leukaemia; Menin inhibitors; KMT2A-rearranged leukaemia; Targeted therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [Menin](https://onco.cc/targets/menin/)
- drugs: [Revumenib](https://onco.cc/drugs/revumenib/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [AUGMENT-101](https://onco.cc/trials/augment-101/)
- key papers: [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/ghayas-issa.json